Mutant IDH : A Targetable Driver of Leukemic Phenotypes Linking Metabolism, Epigenetics and Transcriptional Regulation

Garrett-Bakelman, Francine E; Melnick, Ari M

doi:10.2217/epi-2016-0008

Cited by 25Acute Myeloid Leukemia ResearchEpigenetics and DNA MethylationChromatin Remodeling and Cancer

Mutant IDH : A Targetable Driver of Leukemic Phenotypes Linking Metabolism, Epigenetics and Transcriptional Regulation

Open access

Garrett-Bakelman, Francine E, Melnick, Ari M·2016·Epigenomics

DOI 10.2217/epi-2016-0008PMC PMC5066133

Open this paper in CoChat — free account

Abstract

Aberrant epigenomic programming is a hallmark of acute myeloid leukemia. This is partially due to somatic mutations that perturb cytosine methylation, histone post-translational modifications and transcription factors. Remarkably, mutations in the IDH1 and IDH2 genes perturb the epigenome through all three of these mechanisms. Mutant IDH enzymes produce high levels of the oncometabolite (R)-2-hydroxyglutarate that competitively inhibits dioxygenase enzymes that modify methylcytosine to hydroxymethylcytosine and histone tail methylation. The development of IDH mutant specific inhibitors may now enable the therapeutic reprogramming of both layers of the epigenome spontaneously to revert the malignant phenotype of these leukemias and improve clinical outcome for acute myeloid leukemia patients with IDH mutations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2217/epi-2016-0008

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Most histone modifying enzymes also methylate non-histone substrates, such as the tumour suppressor p53 protein.
“This situation is further compounded by (i) most histone modifying enzymes also methylating non-histone substrates, such as the tumour suppressor p53 protein 36 ,”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [36]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · see citing works
A 3D Map of the Human Genome at Kilobase Resolution Reveals Principles of Chromatin Looping
Rao, S. S. P., Huntley, M. H., Durand, N. C., Stamenova, E. K., Bochkov, I. D., Robinson, J. T., Sanborn, A. L., Machol, I., Omer, A. D., Lander, E. S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.021 · Cited by 9,212 · see citing works
High-Resolution Profiling of Histone Methylations in the Human Genome
Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Schones, D. E., Wang, Z., Wei, G., Chepelev, I., & Zhao, K. (2007) · Cell · doi:10.1016/j.cell.2007.05.009 · Cited by 6,845 · see citing works
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061 · see citing works
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · see citing works
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836 · see citing works
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078 · see citing works
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,834 · see citing works
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154 · see citing works
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · see citing works
Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA
He, Y., Li, B.-Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., et al. (2011) · Science · doi:10.1126/science.1210944 · Cited by 2,776 · see citing works
The complex language of chromatin regulation during transcription
Berger, S. L. (2007) · Nature · doi:10.1038/nature05915 · Cited by 2,768 · see citing works
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · see citing works
Self-citation
Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622 · see citing works
Histone methylation: a dynamic mark in health, disease and inheritance
Greer, E. L., & Shi, Y. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3173 · Cited by 2,241 · see citing works
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219 · see citing works
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020 · see citing works
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985 · see citing works
Self-citation
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974 · see citing works
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,936 · see citing works
Self-citation
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791 · see citing works
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693 · see citing works
Insulator dysfunction and oncogene activation in IDH mutant gliomas
Flavahan, W. A., Drier, Y., Liau, B. B., Gillespie, S. M., Venteicher, A. S., Stemmer-Rachamimov, A. O., Suvà, M. L., & Bernstein, B. E. (2016) · Nature · doi:10.1038/nature16490 · Cited by 1,288 · see citing works
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,283 · see citing works
Targeting bromodomains: epigenetic readers of lysine acetylation
Filippakopoulos, P., & Knapp, S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4286 · Cited by 1,274 · see citing works
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Kantarjian, H. M., Thomas, X., Dmoszyńska, A., Wierzbowska, A., Mazur, G. J., Mayer, J., Gau, J., Chou, W., Buckstein, R. J., Čermák, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,170 · see citing works
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153 · see citing works
Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation
Ficz, G., Branco, M. R., Seisenberger, S., Santos, F., Krueger, F., Hore, T. A., Marques, C. J., Andrews, S., & Reik, W. (2011) · Nature · doi:10.1038/nature10008 · Cited by 1,123 · see citing works
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · see citing works
Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers
Chi, P., Allis, C. D., & Wang, G. G. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2876 · Cited by 1,099 · see citing works
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035 · see citing works
Base-Resolution Analysis of 5-Hydroxymethylcytosine in the Mammalian Genome
Yu, M., Hon, G. C., Szulwach, K. E., Song, C., Zhang, L., Kim, A., Li, X., Dai, Q., Shen, Y., Park, B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.027 · Cited by 1,022 · see citing works
TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity
Williams, K., Christensen, J., Pedersen, M. T., Johansen, J. V., Cloos, P. A. C., Rappsilber, J., & Helin, K. (2011) · Nature · doi:10.1038/nature10066 · Cited by 1,021 · see citing works
MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system
Mellén, M., Ayata, P., Dewell, S., Kriaucionis, S., & Heintz, N. (2012) · Cell · doi:10.1016/j.cell.2012.11.022 · Cited by 943 · see citing works
Understanding the language of Lys36 methylation at histone H3
Wagner, E. J., & Carpenter, P. B. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3274 · Cited by 933 · see citing works
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Figueroa, M. E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C. A. J., Deng, X., Christos, P. J., Schifano, E. D., Booth, J. G., van Putten, W., Skrabanek, L. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.020 · Cited by 833 · see citing works
Self-citation
Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells
Pastor, W. A., Pape, U. J., Huang, Y., Henderson, H. R., Lister, R., Ko, M., McLoughlin, E. M., Brudno, Y., Mahapatra, S., Kapranov, P., et al. (2011) · Nature · doi:10.1038/nature10102 · Cited by 804 · see citing works
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804 · see citing works
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Marcucci, G., Maharry, K. S., Wu, Y.-Z., Radmacher, M. D., Mrózek, K., Margeson, D., Holland, K. B., Whitman, S. P., Becker, H., Schwind, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3730 · Cited by 763 · see citing works
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736 · see citing works
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727 · see citing works
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703 · see citing works
Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b
Kroon, E., Krosl, J., Thorsteinsdottir, U., Baban, S., Buchberg, A. M., & Sauvageau, G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.13.3714 · Cited by 640 · see citing works
Genome-wide Regulation of 5hmC, 5mC, and Gene Expression by Tet1 Hydroxylase in Mouse Embryonic Stem Cells
Xu, Y., Wu, F., Tan, L., Kong, L., Xiong, L., Deng, J., Barbera, A. J., Zheng, L., Zhang, H., Huang, S., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.04.005 · Cited by 634 · see citing works
Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cellsPreprint
Wu, H., D’Alessio, A. C., Ito, S., Wang, Z., 崔凯荣, Zhao, K., Sun, Y. E., & Zhang, Y. (2011) · Genes & Development · doi:10.1101/gad.2036011 · Cited by 585 · see citing works
The alternative role of DNA methylation in splicing regulation
Lev-Maor, G., Yearim, A., & Ast, G. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.03.002 · Cited by 566 · see citing works
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism
Reitman, Z. J., & Yan, H. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq187 · Cited by 562 · see citing works
Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition
Maunakea, A. K., Chepelev, I., Cui, K., & Zhao, K. (2013) · Cell Research · doi:10.1038/cr.2013.110 · Cited by 552 · see citing works
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Sasaki, M., Knobbe, C. B., Munger, J. C., Lind, E. F., Brenner, D., Brüstle, A., Harris, I. S., Holmes, R., Wakeham, A., Haight, J., et al. (2012) · Nature · doi:10.1038/nature11323 · Cited by 513 · see citing works
Self-citation
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
Cairns, R. A., Iqbal, J., Lemonnier, F., Küçük, C., de Leval, L., Jaïs, J., Parrens, M., Martin, A., Xerri, L., Brousset, P., et al. (2012) · Blood · doi:10.1182/blood-2011-11-391748 · Cited by 505 · see citing works
Signals and Combinatorial Functions of Histone Modifications
Suganuma, T., & Workman, J. L. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061809-175347 · Cited by 498 · see citing works
5-Hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells
Stroud, H., Feng, S., Kinney, S. R. M., Pradhan, S., & Jacobsen, S. E. (2011) · Genome biology · doi:10.1186/gb-2011-12-6-r54 · Cited by 466 · see citing works
RUNX1Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
Gaidzik, V. I., Bullinger, L., Schlenk, R. F., Zimmermann, A., Röck, J., Paschka, P., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7926 · Cited by 454 · see citing works
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
Reitman, Z. J., Jin, G., Karoly, E. D., Spasojevic, I., Yang, J., Kinzler, K. W., He, Y., Bigner, D. D., Vogelstein, B., & Yan, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019393108 · Cited by 449 · see citing works
Transcriptional control of granulocyte and monocyte development
Friedman, A. D. (2007) · Oncogene · doi:10.1038/sj.onc.1210764 · Cited by 427 · see citing works
IDH mutations in glioma and acute myeloid leukemia
Dang, L., Jin, S., & Su, S.-S. M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.002 · Cited by 368 · see citing works
MeCP2 binds to 5hmc enriched within active genes and accessible chromatin in the nervous system
Mellén, M., Ayata, P., Dewell, S. B., Kriaučionis, S., & Heintz, N. (2013) · Epigenetics & Chromatin · doi:10.1186/1756-8935-6-s1-p52 · Cited by 345 · see citing works
WT1 Recruits TET2 to Regulate Its Target Gene Expression and Suppress Leukemia Cell Proliferation
Wang, Y., Xiao, M., Chen, X., Chen, L., Xu, Y., Lv, L., Wang, P., Yang, H., Ma, S., Lin, H., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.023 · Cited by 304 · see citing works
Base-Pair Resolution DNA Methylation Sequencing Reveals Profoundly Divergent Epigenetic Landscapes in Acute Myeloid Leukemia
Akalin, A., Garrett-Bakelman, F. E., Kormaksson, M., Busuttil, J., Zhang, L., Khrebtukova, I., Milne, T. A., Huang, Y., Biswas, D., Hess, J. L., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002781 · Cited by 296 · see citing works
Self-citation
Integrating 5-Hydroxymethylcytosine into the Epigenomic Landscape of Human Embryonic Stem Cells
Szulwach, K. E., Li, X., Li, Y., Song, C., Han, J. W., Kim, S., Namburi, S., Hermetz, K. E., Kim, J. J., Rudd, M. K., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002154 · Cited by 288 · see citing works
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
Green, C. L., Evans, C. M., Zhao, L., Hills, R. K., Burnett, A. K., Linch, D. C., & Gale, R. E. (2011) · Blood · doi:10.1182/blood-2010-12-322479 · Cited by 270 · see citing works
Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis
Rasmussen, K. D., Jia, G., Johansen, J. V., Pedersen, M. T., Rapin, N., Bagger, F. O., Porse, B. T., Bernard, O. A., Christensen, J., & Helin, K. (2015) · Genes & Development · doi:10.1101/gad.260174.115 · Cited by 270 · see citing works
DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia
Rampal, R. K., Akalin, A., Madžo, J., Vasanthakumar, A., Pronier, E., Patel, J. L., Li, Y., Ahn, J., Abdel-Wahab, O. I., Shih, A. H., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.004 · Cited by 267 · see citing works
Self-citation
PU.1 target genes undergo Tet2-coupled demethylation and DNMT3b-mediated methylation in monocyte-to-osteoclast differentiation
de la Rica, L., Rodríguez-Ubreva, J., García, M., Islam, A. B., Urquiza, J. M., Hernando, H., Christensen, J., Helin, K., Gómez-Vaquero, C., & Ballestar, E. (2013) · Genome Biology · doi:10.1186/gb-2013-14-9-r99 · Cited by 211 · see citing works
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
Chaturvedi, A., Araujo Cruz, M. M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491571 · Cited by 210 · see citing works
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
Dinardo, C. D., PROPERT, K. J., Loren, A. W., Paietta, E. M., Sun, Z., Levine, R. L., Straley, K. S., Yen, K. E., Patel, J. P., Agresta, S. V., et al. (2013) · Blood · doi:10.1182/blood-2013-03-493197 · Cited by 197 · see citing works
Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance
Kats, L. M., Reschke, M., Taulli, R., Pozdnyakova, O., Burgess, K., Bhargava, P., Straley, K. S., Karnik, R., Meissner, A., Small, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2013.12.016 · Cited by 187 · see citing works
TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group
Gaidzik, V. I., Paschka, P., Späth, D., Habdank, M., Köhne, C.-H., Germing, U., von Lilienfeld-Toal, M., Held, G., Horst, H.-A., Haase, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2886 · Cited by 185 · see citing works
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibitionPreprint
Chen, C., Liu, Y., Lü, C., Cross, J. R., Morris, J. P., Shroff, A., Ward, P. S., Bradner, J. E., Thompson, C. B., & Lowe, S. W. (2013) · Genes & Development · doi:10.1101/gad.226613.113 · Cited by 182 · see citing works
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Okoye-Okafor, U. C., Bartholdy, B., Cartier, J., Gao, E. N., Pietrak, B., Rendina, A. R., Rominger, C., Quinn, C., Smallwood, A., Wiggall, K. J., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1930 · Cited by 180 · see citing works
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
Kernytsky, A. M., Wang, F., Hansen, E., Schalm, S. S., Straley, K. S., Gliser, C., Yang, H. Q., Travins, J. M., Murray, S., Dorsch, M., et al. (2014) · Blood · doi:10.1182/blood-2013-10-533604 · Cited by 174 · see citing works
TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State
Cardaci, S., & Ciriolo, M. R. (2012) · International Journal of Cell Biology · doi:10.1155/2012/161837 · Cited by 162 · see citing works
The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Geyer, S. M., Bloomfield, C. D., Döhner, K., Thiede, C., Marcucci, G., Lo‐Coco, F., Klisovic, R. B., et al. (2015) · Blood · doi:10.1182/blood.v126.23.6.6 · Cited by 159 · see citing works
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)
Herrmann, H., Blatt, K., Shi, J., Gleixner, K. V., Cerny‐Reiterer, S., Müllauer, L., Vakoc, C. R., Sperr, W. R., Horny, H., Bradner, J. E., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.733 · Cited by 157 · see citing works
Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations
Emadi, A., Jun, S. A., Tsukamoto, T., Fathi, A. T., Minden, M. D., & Dang, C. V. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.12.001 · Cited by 152 · see citing works
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status
Green, C. L., Evans, C. M., Hills, R. K., Burnett, A. K., Linch, D. C., & Gale, R. E. (2010) · Blood · doi:10.1182/blood-2010-02-270926 · Cited by 137 · see citing works
Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model
Li, L., Piloto, O., Nguyen, H. B., Greenberg, K. E., Takamiya, K., Racke, F. K., Huso, D. L., & Small, D. (2008) · Blood · doi:10.1182/blood-2007-08-109942 · Cited by 129 · see citing works
Translational implications of somatic genomics in acute myeloid leukaemia
Meyer, S. C., & Levine, R. L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70008-7 · Cited by 125 · see citing works
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
Fathi, A. T., Sadrzadeh, H., Borger, D. R., Ballen, K. K., Amrein, P. C., Attar, E. C., Foster, J., Burke, M. E., Lopez, H. U., Matulis, C. R., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438267 · Cited by 123 · see citing works
Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia
Wang, J., Liu, Y., Li, Z., Du, J., Ryu, M., Taylor, P. R., Fleming, M. D., Young, K. H., Pitot, H. C., & Zhang, J. (2010) · Blood · doi:10.1182/blood-2010-04-281527 · Cited by 118 · see citing works
Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
Li, L., Paz, A. C., Wilky, B. A., Johnson, B. A., Galoian, K. A., Rosenberg, A. E., Hu, G., Tinoco, G., Bodamer, O. A., & Trent, J. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133813 · Cited by 107 · see citing works
MeCP2: structure and functionThis paper is one of a selection of papers published in a Special Issue entitled 31st Annual International Asilomar Chromatin and Chromosomes Conference, and has undergone the Journal’s usual peer review process.
Adkins, N. L., & Georgel, P. T. (2011) · Biochemistry and Cell Biology · doi:10.1139/o10-112 · Cited by 98 · see citing works
Tet2 Facilitates the Derepression of Myeloid Target Genes during CEBPα-Induced Transdifferentiation of Pre-B Cells
Kallin, E. M., Rodríguez-Ubreva, J., Christensen, J., Cimmino, L., Aifantis, I., Helin, K., Ballestar, E., & Graf, T. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.08.007 · Cited by 92 · see citing works
Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial
Stein, E. M., Dinardo, C. D., Altman, J. K., Collins, R. H., DeAngelo, D. J., Kantarjian, H. M., Sekeres, M. A., Fathi, A. T., Flinn, I. W., Frankel, A. E., et al. (2015) · Blood · doi:10.1182/blood.v126.23.323.323 · Cited by 72 · see citing works
Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice
Mylonas, E., Janin, M., Bawa, O., Opolon, P., David, M. D., Quivoron, C., Bernard, O., Ottolenghi, C., Debotton, S., & Penard‐Lacronique, V. (2014) · Leukemia · doi:10.1038/leu.2014.18 · Cited by 20 · see citing works
A Novel Inhibitor of Mutant IDH1 Induces Differentiation in Vivo and Prolongs Survival in a Mouse Model of Leukemia
Chaturvedi, A., Cruz, M. M. A., Goparaju, R., Jyotsana, N., Baehre, H., Görlich, K., Schottmann, R., Preller, M., Struys, E. A., Kloos, A., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3598.3598 · Cited by 8 · see citing works
BCL-2 Inhibition As a Synthetic Lethal Approach To Target Isocitrate Dehydrogenase Mutations In Acute Myeloid Leukemia Stem Cells
Chan, S. M., Medeiros, B. C., & Majeti, R. (2013) · Blood · doi:10.1182/blood.v122.21.885.885 · Cited by 6 · see citing works

Flagged first, then by citations

Sorted by citations

The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549 · see citing works
The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues
Goetzman, E. S., & Prochownik, E. V. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00129 · Cited by 199 · see citing works
“d-R-2HG is a potent inhibitor of the Ten–Eleven Translocation 2 protein that normally converts 5-methylcytosine to 5-hydroxymethylcytosine, a reaction that serves as an intermediate step in DNA de-methylation (32, 36, 37).”
Background
The Role of IDH Mutations in Acute Myeloid Leukemia
Bravo, G. M., & Dinardo, C. D. (2018) · Future Oncology · doi:10.2217/fon-2017-0523 · Cited by 123 · see citing works
The Process and Regulatory Components of Inflammation in Brain Oncogenesis
Mostofa, A., Punganuru, S. R., Madala, H. R., Al-Obaide, M., & Srivenugopal, K. S. (2017) · Biomolecules · doi:10.3390/biom7020034 · Cited by 115 · see citing works
The effects of mutational processes and selection on driver mutations across cancer types
Temko, D., Tomlinson, I. P. M., Severini, S., Schuster-Böckler, B., & Graham, T. A. (2018) · Nature Communications · doi:10.1038/s41467-018-04208-6 · Cited by 115 · see citing works
IDH Mutation, Competitive Inhibition of FTO, and RNA Methylation
Elkashef, S. M., Lin, A.-P., Myers, J., Sill, H., Jiang, D., Dahia, P. L. M., & Aguiar, R. C. T. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.001 · Cited by 78 · see citing works
“Competitive inhibition of the a-KG-dependent DNA hydroxylases (TET family) and Jumonji family histone demethylases, and an attendant hypermethylator phenotype, is characteristic of IDH-mutant AMLs (Garrett-Bakelman and Melnick, 2016).”
Background
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML
Duy, C., Teater, M. R., Garrett-Bakelman, F. E., Lee, T. C., Meydan, C., Glass, J. L., Li, M., Hellmuth, J. C., Mohammad, H. P., Smitheman, K. N., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0106 · Cited by 46 · see citing works
Self-citation
Enasidenib and ivosidenib in AML
Martelli, M. P., Martino, G., Cardinali, V., Falini, B., Martinelli, G., & Cerchione, C. (2020) · Minerva Medica · doi:10.23736/s0026-4806.20.07024-x · Cited by 42 · see citing works
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
Megías‐Vericat, J. E., Ballesta‐López, O., Barragán, E., & Montesinos, P. (2019) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s177913 · Cited by 35 · see citing works
“Biochemical studies have shown that D2HG production can potentially affect epigenetic regulation and cell differentiation through inhibition of both histone and DNA demethylation.(11) In AML, the most frequently detected IDH1 is located in the Arg132 residue (R132), modifying the substrate-binding arginine of the enzy…”
Background
AML and the art of remission maintenance
Lima, M. J. G. D., Roboz, G. J., Platzbecker, U., Craddock, C., & Ossenkoppele, G. J. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100829 · Cited by 30 · see citing works
Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma
Lu, H., Yang, S., Zhu, H., Tong, X., Xie, F., Qin, J., Han, N., Wu, X., Fan, Y., Shao, Y. W., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4159-2 · Cited by 29 · see citing works
“G395A) 8 Response to IDH1 and pan-IDH inhibitors (active clinical trial) [31]”
Background
Gene expression model inference from snapshot RNA data using Bayesian non-parametrics
Kilic, Z., Schweiger, M., Moyer, C., Shepherd, D. P., & Pressé, S. (2023) · Nature Computational Science · doi:10.1038/s43588-022-00392-0 · Cited by 29 · see citing works
The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome
Zheng, L., Zhang, L., Guo, Y., Xu, X., Liu, Z., Yan, Z., & Fu, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1078421 · Cited by 15 · see citing works
Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia
Sunthankar, K. I., Jenkins, M. T., Cote, C. H., Patel, S. B., Welner, R. S., & Ferrell, P. B. (2021) · Leukemia · doi:10.1038/s41375-021-01487-9 · Cited by 12 · see citing works
Emerging pharmacotherapies for elderly acute myeloid leukemia patients
Thomas, X., Elhamri, M., & Heiblig, M. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1758058 · Cited by 11 · see citing works
“on histone modifications and transcriptional regulation [31] (Figure 2).”
Background
Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors
Tecik, M., & Adan, A. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01202-7 · Cited by 9 · see citing works
“Hence, IDH1/2 mutations and 2-HG accumulation result in inhibition of blocked differentiation of HSCs and enhanced self-renewal through inhibition of DNA and histone demethylation [182].”
Background
Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation
Wen, F., Gui, G., Wang, X., Qin, A., Ma, T., Chen, H., Li, C., & Zha, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02482 · Cited by 8 · see citing works
A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
Yin, J., Wan, C., Zhang, L., Zhang, H., Bai, L., Zhou, H., Xu, M., Chen, L., Qian, C., Qiu, H.-Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.726926 · Cited by 8 · see citing works
Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes
Papadopoulou, V., Schoumans, J., Basset, V., Solly, F., Pasquier, J., Blum, S., & Spertini, O. (2023) · Hematology · doi:10.1080/16078454.2023.2180704 · Cited by 7 · see citing works
Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCRTM In Patients With AML And Their Clinical Impact In Mexico City
Olarte-Carrillo, I., Laguna, A. I. G., Peñafiel, C. O. R., Arratia, B., Centeno-Cruz, F., Sanchez, J. P., Füller, E. R., Ipiña, J. J. K., Jaloma, J. C., & Tovar, A. M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s219703 · Cited by 7 · see citing works
“mutations are associated with chromatin alterations, including global histone alterations and DNA methylation.(25,26) It is important to identify the presence of IDH1/2 mutations in a rapid manner so that patients can benefit from”
Background
5-methylcytosine RNA modification regulators-based patterns and features of immune microenvironment in acute myeloid leukemia
Ding, Y., Bajpai, A. K., Wu, F., Lu, W., Xu, L., Mao, J., Li, Q., Pan, Q., Lu, L., & Wang, X. (2024) · Aging · doi:10.18632/aging.205484 · Cited by 5 · see citing works
Characteristics and Prognosis of “Acute Promyelocytic Leukemia-like” Nucleophosmin-1-Mutated Acute Myeloid Leukemia in a Retrospective Patient Cohort
Papadopoulou, V., Schiavini, G., Stalder, G., Basset, V., Schoumans, J., Nabergoj, M., & Schaller, M. (2024) · Biomedicines · doi:10.3390/biomedicines12102282 · Cited by 4 · see citing works
“As hydroxylation of the 5-methylcytosines of DNA is the first step towards DNA demethylation [26,27], the activity of IDH1/2 enzymes ultimately promotes DNA and histone demethylation by providing a-KG to dioxygenases [28].”
Background
Evolution of Epigenome as the Blueprint for Carcinogenesis
Farooq, Z., Shah, A. T., Tauseef, M., Rather, R. A., & Anwar, M. (2021) · Biochemistry · doi:10.5772/intechopen.97379 · Cited by 4 · see citing works
Integrated single-cell and bulk transcriptomic profiling reveals coagulation-associated heterogeneity and prognostic SPINT2 in acute myeloid leukemia
Wang, Z., Han, M., Zhang, D., Cui, L., Zhang, L., & Wang, B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1971923
BindingDB Entry 50021058: Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation.
BindingDB (2025) · UC San Diego · doi:10.7270/q2794995

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
Nassereddine, S., Lap, C. J. G., Haroun, F., & Tabbara, I. A. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3161-0 · Cited by 68 · see citing works
Mutation-Selective IDH Inhibitors Mediate Histone and Dna Methylation Changes
Agresta, S., & Yen, K. E. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt042.23 · Cited by 1 · see citing works
Targeting Metabolic Inputs into Epigenetic Regulations of Acute Leukemia
Thompson, C. B. (2013) · Blood · doi:10.1182/blood.v122.21.sci-26.sci-26 · Cited by 2 · see citing works
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
Chaturvedi, A., Araujo Cruz, M. M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491571 · Cited by 210 · see citing works
Abstract PL02-04: IDH mutations and tumorigenicity.
Wang, F., Travins, J. M., DeLaBarre, B., Penard‐Lacronique, V., Schalm, S. S., Hansen, E., Straley, K. S., Kernytsky, A. M., Liu, W., Gliser, C., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-pl02-04 · Cited by 1 · see citing works

Authors: Garrett-Bakelman, F. E., & Melnick, A. M.
Affiliations: Weill Cornell Medicine (US)
ORCID: Garrett-Bakelman, Francine E
Melnick, Ari M
Venue: Epigenomics
Publisher: Informa UK Limited
Published: 2016-07
Volume: 8
Issue: 7
Pages: 945-957
ISSN: 1750-1911 (ISSN-L)
1750-192X
DOI: 10.2217/epi-2016-0008
PMC: PMC5066133
OpenAlex: W2484912202
Cited by: 25
References: 88
Citations by year: 2026: 1 · 2025: 1 · 2024: 4 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 2
FWCI: 0.47
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Epigenomics (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (K08CA169055, R01CA198089)
American Society of Hematology (ASHAMFDP-20121)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: IDH1 mutation, IDH2 mutation, acute myeloid leukemia, 2-hydroxyglutarate, oncometabolites, DNA hydroxymethylation, histone methylation, cytosine methylation, epigenetic reprogramming, IDH inhibitors, transcriptional regulation, histone modifications
MeSH terms: Animals, Humans, Isocitrate Dehydrogenase, Mutation, Phenotype, Transcription, Genetic, Gene Expression Regulation, Leukemic, Epigenesis, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutant IDH : A Targetable Driver of Leukemic Phenotypes Linking Metabolism, Epigenetics and Transcriptional Regulation

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks